Anti-CD19 CAR T Kymriah and Yescarta Race to Market Infographic
September 1, 2019
Two anti-CD19 CAR T cell therapies are currently approved by the FDA to treat hematologic malignancies: Kymriah and Yescarta. Both therapies have the same mechanism of action and treat relapsed/refractory B-cell malignancies such as acute lymphoblastic leukemia (ALL) and large B-cell lymphoma (LBCL). Click to zoom in.
Anti-CD19 CAR T Race to Market

The infographic below shows the path to market from pre-IND for these two FDA-approved anti-CD19 CAR T cell therapies. Zoom in or click the full screen button to see the details.



Selected takeaways
  • The race was indeed tight. The leader switched multiple times during the clinical development and regulatory review process.
  • It is critical to have smooth commercial manufacturing of autologous cell therapy product. It’s even more important when competing with other investigational products recruiting the same patient population.
  • Kymriah might have been approved for the treatment of r/r DLBCL much earlier. However, the FDA pushed back the cut-off date for efficacy/safety data by 6 months. With now FDA-approved anti-CD19 CAR T, Novartis had to elaborate on Kymriah’s advantages over Yescarta in the BLA submission. In contrast, Yescarta’s regulatory package discusses only sub-optimal chemotherapy regimens.
We welcome any questions or requests at info@bioheights.com. If you would like to get a downloadable and editable version of the infographic, you can get it here, both in PDF and PowerPoint formats.

To find more interesting articles visit our Insights page.

Disclaimer: All information on the infographic is in the public domain. Sources include the FDA public documents, press releases, clinical trials, etc. BioHeights LLC and its members have never had and do not currently have any confidential information related to these products.
Sickle Cell Disease: Centers of Excellence And Gene Therapy
July 11, 2020
Ohio Cell and Vector Manufacturing Landscape
May 15, 2020
Educational Webinars: Forecasting Principles And Tools
April 8, 2020
Risk-Adjusted NPV Calculator – Free Tool
March 21, 2020
NRA NPV Forecast For Investigational Product – Free Tool
March 11, 2020
CAR T Release Testing Basics
February 21, 2020
Revenue Forecast For Investigational Therapeutic – Free Tool
February 19, 2020
The Man Who Speaks on Behalf of ALL Children
October 17, 2019
Anti-CD19 CAR T Kymriah and Yescarta Race to Market Infographic
September 1, 2019
Jeff Marrazzo Tells His Spark Story
July 1, 2019
ASGCT 2019 Insights: Cell and Gene Therapies Tackle 160+ Disorders
May 10, 2019
AAV Gene Therapy Clinical Trials Target Over 50 Diseases
April 1, 2019
13 Different Routes of Administration in AAV Gene Therapy Clinical Trials
March 1, 2019